Chronic Refractory Gout Pharmaceuticals Market Size, Share, Growth, Trends, and Global Industry Analysis: By Drug Type (Xanthine Oxidase Inhibitors, Uricosuric Medications, Uricases and Others), By End Users (Hospitals, Clinical diagnostic laboratories, Other) and Region Forecast 2019-2030

Chronic Refractory Gout Pharmaceuticals Market size was value US$ 1,839.2 million in 2023 and is projected to reach a value of US$ 2,914.9 million by 2030, at a CAGR of 6.8% from 2024-2030. Gout is the most common type of inflammatory arthritis in the world and is caused by the buildup of uric acid crystals in your joints. These crystals form when there’s too much uric acid in your blood. In the United States, gout affects 5% of the population. Of those with gout, fewer than 2% have chronic refractory gout. Refractory gout is a rare condition where gout symptoms are ongoing and resistant to treatment. With refractory gout, the body is unable to maintain a target serum urate level of less than 6 mg/dl.

The global population of individuals with gout increased in the past 30 years from 22 million to 53 million. Among EU5 countries, Germany had the highest Chronic Gout prevalence in 2018. The major Chronic Gout therapies available in the Chronic Gout market are aimed at timely relief of pain and disability caused by intense inflammation. Nonsteroidal anti-inflammatory drugs (NSAIDs), such as colchicine, are commonly used as the first line of therapy for Chronic Gout treatment. However, glucocorticoids or corticotropin are used when NSAIDs and colchicine are contraindicated. The main treatments used for this disease are the xanthine oxidase inhibitors (allopurinol and febuxostat, etc), uricosuric medications (benzbromarone, probenecid, and sulfinpyrazone, etc). The main drivers of the market are the prevalence of the disease and the ongoing research in the advancements.

Additionally, obesity and dietary factors are one of the major contributors for the prevalence of gout. The limitations of this market are the high costs of the R&D activities plus, the ineffectiveness of the treatment. Sometimes, in many cases resistance builds overtime for the prescribed treatment, which in turn declines the sales of the drugs. Moreover, reduced treatment option availabilities and high cost of the high effective medicines also pose as restraints for the market expansion. The market poses a huge opportunity as the number of chronic gout cases increases over time especially in high and middle SDI countries, and the use of combination therapies and novel therapies.

Key Developments

• In Aug 2024, Sweden’s Sobi has kicked off a rolling biologics license application in the US for SEL-212, vying to become a new option for patients with refractory chronic gout that doesn’t respond to current treatments.
• In March 21, 2023 - Protalix BioTherapeutics, Inc announced that the first patient has been dosed in the Company's phase I First in Human (FIH) clinical trial of PRX-115, the Company's recombinant PEGylated uricase product candidate under development as a potential treatment of severe gout.
• In May 2021, Fortress Biotech announced that it had entered into an exclusive licensing agreement with Fuji Yakuhin Co. Ltd. to develop Dotinurad in the United States, United Kingdom, European Union and Canada.